| Over a week ago |
|
Upgrade
|
Catch up on today's… Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pinnacle West (PNW) upgraded to Overweight from Equal Weight at Barclays with analyst Eric Beaumont saying the shares are undervalued given the regulatory overhang and uncertainty associated with expected Arizona Commission Corporation turnover. 2. Amedisys (AMED) upgraded to Buy from Hold at Benchmark with analyst Bill Sutherland saying he believes the home health book of business is nearing pre-COVID levels of activity, while also contending that COVID-19 has enhanced the preference for home health over skilled nursing facilities and nursing homes. 3. BMC Stock Holdings (BMCH) upgraded to Buy from Hold at Benchmark with analyst Reuben Garner saying he thinks housing demand is improving by the day, while supply is increasingly limited, and he now believes that valuation for the group, and for BMC, could continue to move higher as the market starts to anticipate rising earnings estimates. 4. Church & Dwight (CHD) upgraded to Outperform from Neutral at Credit Suisse with analyst Kaumil Gajrawala saying the company's operating model is "designed to thrive in this environment." 5. CNO Financial (CNO) upgraded to Buy from Neutral at Goldman Sachs with analyst Alex Scott saying the shares are trading at 5.6 times on 2021 estimated free cash flow versus the sector average of 9.5 times which underappreciates the company's ability to consistently return cash to shareholders. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. ShowHide Related Items >><< - 05/01/20
- Paylocity to replace Meredith in S&P 400 at open on 5/1
- 04/27/20
- S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices
- 04/06/20
- Paylocity acquires VidGrid, terms not disclosed
- 06/02/20
- CNO Financial names Chief Actuary Karen DeToro as CRO, effective June 15
- 05/08/20
- CNO Financial raises quarterly dividend to 12c from 11c per share
- 01/14/20
- CNO Financial announces new operating model, sees Q4 pre-tax charge of $14M
- 04/30/20
- Church & Dwight declares quarterly dividend of 24c
- 03/24/20
- Church & Dwight draws down $825M of its $1B credit facility
- 01/31/20
- Church & Dwight increases dividend 5.5% to 24c per share
- 05/05/20
- BMC Stock Holdings temporarily suspending share repurchase program
- 05/05/20
- BMC Stock Holdings creates cross-function task force for COVID-19 response
- 04/06/20
- BMC Stock Holdings takes steps to reduce operating expenses
- 04/06/20
- BMC Stock Holdings 'significantly' reduces operations in State of Washington
- 04/27/20
- Amedisys to acquire AseraCare Hospice for $235M in cash
- 04/17/20
- Amedisys receives cash payment of $96M in CARES Act assitance
- 02/18/20
- Fly Intel: After Hours Movers
- 02/18/20
- Amedisys reports Q4 adj. EPS 94c, consensus 93c
- 06/18/20 Barclays
- Pinnacle West upgraded to Overweight with $89 target at Barclays
- 06/18/20 Barclays
- Pinnacle West upgraded to Overweight from Equal Weight at Barclays
- 06/15/20
- Fly Intel: Top five analyst upgrades
- 06/14/20 Goldman Sachs
- Pinnacle West upgraded to Buy from Neutral at Goldman Sachs
- 06/18/20 Benchmark
- Benchmark upgrades Amedisys to Buy on expected EBITDA improvement
- 06/18/20 Benchmark
- Amedisys upgraded to Buy from Hold at Benchmark
- 05/21/20 SunTrust
- SunTrust raises price targets across select Healthcare Services names
- 05/11/20 Raymond James
- Amedisys price target lowered to $210 from $225 at Raymond James
- 06/18/20 Benchmark
- Benchmark upgrades BMC Stock Holdings to Buy on rising housing market confidence
- 06/18/20 Benchmark
- BMC Stock Holdings upgraded to Buy from Hold at Benchmark
- 06/05/20 Evercore ISI
- BMC Stock Holdings downgraded to In Line from Outperform at Evercore ISI
- 04/13/20 DA Davidson
- BMC Stock Holdings price target lowered to $24 from $34 at DA Davidson
- 06/18/20 RBC Capital
- Paylocity upgraded to Outperform from Sector Perform at RBC Capital
- 06/18/20 RBC Capital
- Paylocity upgraded to Outperform from Sector Perform at RBC Capital
- 05/22/20 Piper Sandler
- Piper expands Software coverage, favors companies that drive automation
- 05/21/20 Piper Sandler
- Paylocity initiated with a Neutral at Piper Sandler
- 06/18/20 Credit Suisse
- Credit Suisse upgrades Church & Dwight, says 'built to withstand' recession
- 06/18/20 Credit Suisse
- Church & Dwight upgraded to Outperform from Neutral at Credit Suisse
- 05/15/20 SunTrust
- Church & Dwight, Colgate Palmolive price targets raised at SunTrust
- 03/26/20 Barclays
- Church & Dwight price target lowered to $55 from $65 at Barclays
- 06/18/20 Goldman Sachs
- CNO Financial upgraded to Buy from Neutral at Goldman Sachs
- 05/29/20 B. Riley FBR
- CNO Financial upgraded to Buy from Neutral at B. Riley FBR
- 05/20/20
- Fly Intel: Top five analyst initiations
- 05/20/20 Piper Sandler
- CNO Financial initiated with a Neutral at Piper Sandler
- 05/08/20
- Pinnacle West backs FY20 EPS view of $4.75-$4.95, consensus $4.81
- 05/08/20
- Pinnacle West reports Q1 EPS 27c, consensus 15c
- 02/21/20
- Pinnacle West backs FY20 EPS view $4.75-$4.95, consensus $4.87
- 02/21/20
- Pinnacle West reports Q4 EPS 57c, consensus 46c
- 05/07/20
- Paylocity sees FY20 revenue $551.7M- $561.7M, consensus $561.2M
- 05/07/20
- Paylocity sees Q4 revenue $121M- $131M, consensus $135.89M
- 05/07/20
- Paylocity reports Q3 EPS 72c, consensus 70c
- 02/04/20
- Paylocity sees FY20 revenue $572.5M-$573.5M, consensus $567.93M
- 02/11/20
- CNO Financial reports Q4 EPS 52c, consensus 46c
- 04/30/20
- Church & Dwight withdraws FY20 guidance
- 04/30/20
- Church & Dwight reports Q1 EPS 83c, consensus 77c
- 04/29/20
- Notable companies reporting before tomorrow's open
- 06/02/20
- BMC Stock Holdings sees Q2 net sales flat to down 5%, consensus $849.78M
- 05/05/20
- BMC Stock Holdings reaffirms withdrawal of FY20 outlook
- 05/05/20
- BMC Stock Holdings reports Q1 adj. EPS 40c, consensus 29c
- 04/06/20
- BMC Stock Holdings withdraws FY20 outlook
- 05/06/20
- Amedisys reports Q1 EPS $1.05, consensus 97c
- 02/18/20
- Amedisys sees FY20 adj. EPS $4.90-$5.13, consensus $4.91
- 05/22/20
- Fly Intel: HP Enterprise, Roku downgrades among today's top calls on Wall Street
- 05/07/20
- Fly Intel: After-Hours Movers
- 04/27/20
- Fly Intel: After-Hours Movers
- 02/18/20
- Fly Insider: Avis, Cabot Microelectronics among week's notable insider trades
- 06/18/20
- Carnival downgrade, Cloudflare upgrade among today's top calls on Wall Street
- 02/21/20
- Early notable gainers among liquid option names on February 21st
- 06/18/20
- Early notable gainers among liquid option names on June 18th
- 06/11/20
- Early notable gainers among liquid option names on June 11th
- 01/31/20
- Early notable gainers among liquid option names on January 31st
|
|
Upgrade
|
As previously reported,… As previously reported, Benchmark analyst Bill Sutherland upgraded Amedisys to Buy from Hold with a $210 price target following the firm's House Call virtual conference earlier this week. He believes the home health book of business is nearing pre-COVID levels of activity, while also contending that COVID-19 has enhanced the preference for home health over skilled nursing facilities and nursing homes, the analyst tells investors. He has raised his estimates to reflect greater visibility into sequential EBITDA improvement in the back half of the year and into 2021, as well as the AseraCare hospice acquisition that closed on June 1. ShowHide Related Items >><< - $179.80 /
+1.415 (+0.79%) - 04/27/20
- Amedisys to acquire AseraCare Hospice for $235M in cash
- 04/17/20
- Amedisys receives cash payment of $96M in CARES Act assitance
- 02/18/20
- Fly Intel: After Hours Movers
- 02/18/20
- Amedisys reports Q4 adj. EPS 94c, consensus 93c
- $179.80 /
+1.415 (+0.79%) - 06/18/20 Benchmark
- Amedisys upgraded to Buy from Hold at Benchmark
- 05/21/20 SunTrust
- SunTrust raises price targets across select Healthcare Services names
- 05/11/20 Raymond James
- Amedisys price target lowered to $210 from $225 at Raymond James
- 05/07/20 Benchmark
- Amedisys downgraded to Hold on limited near-term visibility at Benchmark
- $179.80 /
+1.415 (+0.79%) - 05/06/20
- Amedisys reports Q1 EPS $1.05, consensus 97c
- 02/18/20
- Amedisys sees FY20 adj. EPS $4.90-$5.13, consensus $4.91
|
|
Upgrade
|
Benchmark analyst Bill… Benchmark analyst Bill Sutherland upgraded Amedisys to Buy from Hold with a $210 price target. ShowHide Related Items >><< - $179.80 /
+1.415 (+0.79%) - 04/27/20
- Amedisys to acquire AseraCare Hospice for $235M in cash
- 04/17/20
- Amedisys receives cash payment of $96M in CARES Act assitance
- 02/18/20
- Fly Intel: After Hours Movers
- 02/18/20
- Amedisys reports Q4 adj. EPS 94c, consensus 93c
- $179.80 /
+1.415 (+0.79%) - 05/21/20 SunTrust
- SunTrust raises price targets across select Healthcare Services names
- 05/11/20 Raymond James
- Amedisys price target lowered to $210 from $225 at Raymond James
- 05/07/20 Benchmark
- Amedisys downgraded to Hold on limited near-term visibility at Benchmark
- 05/07/20 Benchmark
- Amedisys downgraded to Hold from Buy at Benchmark
- $179.80 /
+1.415 (+0.79%) - 05/06/20
- Amedisys reports Q1 EPS $1.05, consensus 97c
- 02/18/20
- Amedisys sees FY20 adj. EPS $4.90-$5.13, consensus $4.91
|
|
Conference/Events
|
Virtual Healthcare 1:1… Virtual Healthcare 1:1 Conference will be held on June 15-16 beginning at 9 am. Webcast Link ShowHide Related Items >><< - 05/27/20
- VolitionRx rises ahead of presentation at Maxim's COVID-19 Virtual Conference
- 04/29/20
- VolitionRx's Nu.Q vet assay shows detection of two common canine cancers
- 04/23/20
- VolitionRx files patent for Nu.Q COVID-19 triage test
- 02/20/20
- VolitionRx reports cash and cash equivalents at year-end of $17M
TRHC Tabula Rasa HealthCare - 06/09/20
- Tabula Rasa HealthCare, Regence partner on COVID-19 virtual trial
- 05/27/20
- Tabula Rasa HealthCare announces publication on MedWise Risk Score
- 05/19/20
- TRHC publishes TRHC COVID-19 Treatment and Therapy Digital Resource
- 05/11/20
- Tabula Rasa HealthCare, ASCP sign LOI to offer MedWise
- 04/13/20
- Staar Surgical provides business update amid COVID-19 pandemic
- 02/05/20
- Staar Surgical enters strategic cooperation agreement with SEI
- 02/04/20
- Staar Surgical announces first patient implanted with EVO ICL family of lenses
- 01/13/20
- Staar Surgical receives CE Mark approval for use of ICL as supplemental lens
- 05/28/20
- Seelos Therapeutics initiates preclinical study of SLS-004
- 05/15/20
- Seelos Therapeutics receives Rare Pediatric Disease Designation for SLS-005
- 05/04/20
- Seelos Therapeutics receives notice of allowance for patent for SLS-005
- 04/30/20
- Seelos reports FDA orphan drug designation for SLS-005 in Sanfilippo syndrome
- 04/15/20
- Axovant, Invitae partner to increase access to genetic testing
- 03/23/20
- Invitae, MDA expand access to no-charge genetic testing
- 03/10/20
- Invitae to acquire YouScript for approximately $79.3M and Genelex
- 02/19/20
- Fly Intel: After Hours Movers
- 01/09/20
- Nephros announces launch of PluraPath
- 05/26/20
- NeoGenomics enters strategic collaboration with Inivata
- 05/05/20
- NeoGenomics to collaborate with Bayer to offer NTRK testing
- 04/09/20
- NeoGenomics withdraws FY20 guidance due to COVID-19
- 02/05/20
- NeoGenomics appoints Kathryn McKenzie as CFO, announces additional appointments
- 06/01/20
- Exscribe Orthopaedic Healthcare Solutions selects MTBC Force
- 05/05/20
- MDS Medical selects MTBC Force as RCM services partner
- 04/16/20
- MTBC Health Group Purchasing Organization announces partnerships
- 04/14/20
- MTBC selected by Titan Health Management Solutions to expand RCM services
- 04/19/20
- Fly Intel: Top five weekend stock stories
- 04/09/20
- Livongo Health, Prognos Health partner for more personalized Health Nudges
- 04/03/20
- Kaiser Permanente adding Livongo's digital mental health app myStrength
- 03/12/20
- Livongo Health expands relationship with CVS Health via Point Solutions service
- 06/01/20
- Ligand working with Gilead to meet need for remdesivir
- 05/29/20
- Ligand announces expansion of Icagen license agreement with Roche
- 05/28/20
- Ligand earns $3M milestone payment from Palvella Therapeutics
- 05/06/20
- Ligand sees royalty, contract revenue lower than originally forecasted
- 05/01/20
- Huron trading resumes
- 05/01/20
- Huron trading halted, volatility trading pause
- 04/30/20
- Huron withdraws previously announced full year 2020 guidance
- 04/30/20
- Huron closely monitoring impact of COVID-19 pandemic
- 05/05/20
- Flexion announces virtual poster presentations for FX201
- 05/01/20
- Flexion announces publication of abstracts on patients treated with ZILRETTA
- 04/27/20
- Flexion announces preclinical data supporting development of FX301
- 04/01/20
- Flexion reconfirms at least 10 months of finished goods available in the U.S.
- 05/14/20
- Exact Sciences announces results from Oncotype DX clinical survey at ASCO
- 04/17/20
- Exact Sciences receives FDA EUAoapproval for COVID-19 test
- 03/19/20
- Exact Sciences withdraws Q1, FY20 guidance due to COVID-19
- 03/02/20
- Cigna coverage policy shows Exact Sciences' Cologuard covered every 1-3 years
- 03/17/20
- Catasys appoints Brandon LaVerne as CFO
- 05/06/20
- BioTelemetry withdraws previous financial guidance due to COVID-19
- 04/27/20
- BioTelemetry to hold Annual Stockholder Meeting virtually
- 04/07/20
- BioTelemetry appoints Andrei Stoica as CTO
- 03/25/20
- BioTelemetry expands MCOT service to monitor QT prolongation in COVID-19
- 04/27/20
- Amedisys to acquire AseraCare Hospice for $235M in cash
- 04/17/20
- Amedisys receives cash payment of $96M in CARES Act assitance
- 02/18/20
- Fly Intel: After Hours Movers
- 02/18/20
- Amedisys reports Q4 adj. EPS 94c, consensus 93c
- 05/21/20 SunTrust
- SunTrust raises price targets across select Healthcare Services names
- 05/11/20 Raymond James
- Amedisys price target lowered to $210 from $225 at Raymond James
- 05/07/20 Benchmark
- Amedisys downgraded to Hold on limited near-term visibility at Benchmark
- 05/07/20 Benchmark
- Amedisys downgraded to Hold from Buy at Benchmark
- 01/07/20 SunTrust
- BioTelemetry initiated with a Buy at SunTrust
- 11/06/19 Lake Street
- BioTelemetry price target lowered to $80 from $90 at Lake Street
- 08/02/19
- BioTelemetry downgraded to Market Perform on moderating growth at Raymond James
- 08/02/19 Raymond James
- BioTelemetry downgraded to Market Perform from Outperform at Raymond James
- 05/06/20 RBC Capital
- Short report targeting Catasys 'doesn't break new ground,' says RBC Capital
- 04/20/20 RBC Capital
- Catasys initiated with an Outperform at RBC Capital
- 04/20/20 Canaccord
- Catasys price target raised to $35 from $26 at Canaccord
- 03/16/20 Canaccord
- Canaccord says three focus names names have limited COVID-19 impact
- 05/13/20 Evercore ISI
- Exact Sciences comments imply volumes last week down 40% YoY, says Evercore ISI
- 05/07/20 Craig-Hallum
- Exact Sciences price target lowered to $92 from $99 at Craig-Hallum
- 05/07/20 Canaccord
- Exact Sciences price target lowered to $110 from $120 at Canaccord
- 04/22/20 Baird
- Exact Sciences price target lowered to $90 from $100 at Baird
- 05/27/20 Guggenheim
- Guggenheim starts coverage of four pain treatment makers with two Buys
- 05/26/20 Guggenheim
- Flexion initiated with a Buy at Guggenheim
- 05/08/20 Needham
- Flexion price target lowered to $20 from $30 at Needham
- 04/02/20 Benchmark
- Flexion price target lowered to $17 from $25 at Benchmark
- 05/01/20 Benchmark
- Huron downgraded to Hold on limited visibility at Benchmark
- 05/01/20 Benchmark
- Huron downgraded to Hold from Buy at Benchmark
- 01/06/20 SunTrust
- Huron price target raised to $80 from $74 at SunTrust
- 10/31/19 Barrington
- Huron price target raised to $76 from $68 at Barrington
- 05/06/20 SVB Leerink
- Invitae price target raised to $25 from $20 at SVB Leerink
- 04/02/20 Oppenheimer
- Invitae price target lowered to $25 from $32 at Oppenheimer
- 02/20/20 Cowen
- Invitae price target raised to $30 from $20 at Cowen
- 01/28/20 Cowen
- More flexible Medicare coverage for NGS a positive for Invitae, says Cowen
- 06/02/20 Craig-Hallum
- Ligand stock should move higher, says Craig-Hallum
- 04/29/20 Craig-Hallum
- Ligand has 'significant upside' if remdesivir is approved, says Craig-Hallum
- 04/08/20 H.C. Wainwright
- Ligand price target lowered to $229 from $237 at H.C. Wainwright
- 04/06/20 H.C. Wainwright
- H.C. Wainwright says Captisol a 'key focus' for Ligand, reiterates Buy
- 06/12/20 SVB Leerink
- Livongo Health price target raised to $65 from $55 at SVB Leerink
- 06/05/20 Cowen
- Livongo Health initiated with Outperform at Cowen
- 06/03/20 Canaccord
- Livongo Health price target raised to $69 from $65 at Canaccord
- 05/22/20 JPMorgan
- Livongo Health price target raised to $63 from $36 at JPMorgan
- 06/02/20 Ladenburg
- MTBC initiated with a Buy at Ladenburg
- 03/03/20
- LD Micro to hold a virtual conference
- 03/02/20
- Fly Intel: Top five analyst downgrades
- 03/02/20 H.C. Wainwright
- MTBC downgraded to Neutral from Buy at H.C. Wainwright
- 04/21/20 Stephens
- NeoGenomics resumed with an Overweight at Stephens
- 03/17/20 Needham
- Needham adds NeoGenomics to Conviction List, boosts target to $33
- 03/02/20 Craig-Hallum
- NeoGenomics resumed with a Buy at Craig-Hallum
- 03/02/20 Raymond James
- NeoGenomics price target raised to $32 from $28 at Raymond James
- 01/06/20 Benchmark
- Benchmark names Alibaba, Nvidia, Comcast among best ideas for first half
- 10/24/19 Benchmark
- Nephros initiated with a Speculative Buy at Benchmark
- 10/04/19 Maxim
- Nephros initiated with a Buy rating at Maxim
- 11/18/19 H.C. Wainwright
- Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
- 11/14/19 Benchmark
- Seelos Therapeutics initiated with a Speculative Buy at Benchmark
- 06/15/20 Jefferies
- Staar Surgical initiated with a Buy at Jefferies
- 03/04/20
- BTIG healthcare analysts to hold an analyst/industry conference call
- 01/31/20 Benchmark
- Too early to call China emergency impact on Staar Surgical, says Benchmark
TRHC Tabula Rasa HealthCare - 04/20/20 RBC Capital
- Tabula Rasa HealthCare initiated with an Outperform at RBC Capital
- 04/13/20 Stifel
- Tabula Rasa HealthCare seen as 'one of most defensive names in HCIT' at Stifel
- 04/13/20 SVB Leerink
- Tabula Rasa HealthCare initiated with an Outperform at SVB Leerink
- 03/31/20 Baird
- Tabula Rasa HealthCare resilient in face of COVID-19, says Baird
- 05/06/20 Aegis
- VolitionRx initiated with a Buy at Aegis
TRHC Tabula Rasa HealthCare - 05/07/20
- Tabula Rasa HealthCare backs FY20 revenue view $332M-$352M, consensus $340.37M
- 05/07/20
- Tabula Rasa HealthCare sees Q2 revenue $76M-$81M, consensus $84.66M
- 05/07/20
- Tabula Rasa HealthCare reports Q1 adj. EPS 1c, consensus 0c
- 02/27/20
- Tabula Rasa HealthCare sees Q1 revenue $68.5M-$73.5M, consensus $76.59M
- 05/06/20
- Staar Surgical reports Q1 adjusted EPS 4c, consensus (4c)
- 04/13/20
- Staar Surgical withdraws FY20 guidance due to COVID-19 pandemic
- 04/13/20
- Staar Surgical reports preliminary Q1 revenue $34.9M, consensus $32.22M
- 02/26/20
- Staar Surgical sees FY20 revenue ~$177.2M, consensus $177.48M
- 05/05/20
- Invitae reports Q1 adjusted EPS (80c), consensus (79c)
- 04/01/20
- Invitae withdraws FY20 revenue, test volume, cash burn guidance
- 02/19/20
- Invitae reports Q4 EPS (79c), consensus (65c)
- 01/12/20
- Invitae sees FY20 revenue $330M, consensus $326.77M
- 04/02/20
- Nephros withdraws 2020 revenue guidance
- 04/02/20
- Nephros expects Q1 revenue $2.6M, two est. $3.12M
- 02/27/20
- Nephros reports Q4 adjusted EBITDA $376,000
- 01/06/20
- Nephros sees Q4 revenue $3.2M, consensus $2.7M
- 04/28/20
- NeoGenomics reports Q1 EPS (7c), consensus 2c
- 04/09/20
- NeoGenomics sees Q1 revenue about $106M, consensus $104.42M
- 02/27/20
- NeoGenomics sees FY20 revenue $464M-$474M, consensus $448.31M
- 02/27/20
- NeoGenomics reports Q4 EPS 6c, consensus 6c
- 05/14/20
- MTBC reaffirms FY20 revenue view $100M-$102M, consensus $98.1M
- 05/14/20
- MTBC, Inc reports Q1 adj. EPS 3c, consensus (64c)
- 05/04/20
- MTBC reaffirms FY20 revenue view $100M-$102M, consensus $98.1M
- 04/09/20
- MTBC reaffirms FY20 revenue view $100M-$102M, consensus $100.18M
- 05/06/20
- Livongo Health raises FY20 revenue view to $290M-$303M from $280M-$290M
- 05/06/20
- Livongo Health sees Q2 revenue $73M-$75M, consensus $73.66M
- 05/06/20
- Livongo Health reports Q1 EPS (6c), consensus (4c)
- 05/06/20
- Notable companies reporting after market close
- 05/06/20
- Ligand raises FY220 EPS view to $3.65 from $3.62, consensus $3.57
- 05/06/20
- Ligand reports Q1 adjusted EPS 89c, consensus 66c
- 02/11/20
- Ligand raises FY20 adjusted EPS view to $3.45 from $3.40
- 02/06/20
- Ligand reports Q4 adj. EPS 71c, consensus 63c
- 04/30/20
- Huron reports Q1 adjusted EPS 44c, consensus 38c
- 02/25/20
- Huron sees FY20 adjusted EPS growth 1%-12%, consensus $2.81
- 02/25/20
- Huron reports Q4 adjusted EPS 79c, consensus 64c
- 05/07/20
- Flexion reports Q1 EPS (95c), consensus (99c)
- 04/01/20
- Flexion withdraws 2020 revenue guidance
- 01/09/20
- Flexion sees FY20 product revenue $120M-$135M, consensus $133.24M
- 01/09/20
- Flexion sees Q4 revenue $23.7M, consensus $24.15M
- 05/06/20
- Exact Sciences reports Q1 EPS (71c), consensus (61c)
- 04/21/20
- Exact Sciences reports preliminary Q1 revenue about $348M, consensus $343.04M
- 02/11/20
- Exact Sciences sees FY20 revenue $1.61B-$1.645B, consensus $1.59B
- 02/11/20
- Exact Sciences reports Q4 EPS 54c, may not compare to consensus (35c)
- 05/07/20
- Catasys sees FY20 revenue 'at least' $90M, consensus $87.3M
- 05/07/20
- Catasys reports Q1 EPS (45c), consensus (43c)
- 03/12/20
- Catasys backs FY20 revenue view of $90M, consensus $87.3M
- 03/12/20
- Catasys reports Q4 EPS (39c), two estimates (33c)
- 05/06/20
- BioTelemetry reports Q1 EPS 45c, consensus 43c
- 02/26/20
- BioTelemetry reports Q EPS 48c, consensus 47c
- 05/06/20
- Amedisys reports Q1 EPS $1.05, consensus 97c
- 02/18/20
- Amedisys sees FY20 adj. EPS $4.90-$5.13, consensus $4.91
- 04/18/20
- Teledoc, Livongo among choices to ride digital health wave, Barron's says
- 05/19/20
- Fly Intel: After-Hours Movers
- 04/02/20
- Fly Intel: Pre-market Movers
- 04/01/20
- Fly Intel: After-Hours Movers
- 01/13/20
- Fly Intel: Wall Street's top stories for Monday
- 01/13/20
- Fly Intel: Wall Street's top stories at midday
- 05/06/20
- Fly Intel: After-Hours Movers
- 01/06/20
- Citron reiterates RH as top long, Peloton as top short idea for 2020
- 05/20/20
- Fly Intel: After-Hours Movers
- 12/27/19
- Fly Intel: Wall Street's top stories for Friday
- 12/27/19
- Fly Intel: Wall Street's top stories at midday
- 12/27/19
- Downgrades of Spring Bank, Darden among today's top analyst calls
- 01/02/20
- Six new option listings and two option delistings on January 2nd
- 03/31/20
- Invitae call volume above normal and directionally bullish
- 03/16/20
- Invitae put volume heavy and directionally bearish
- 03/11/20
- Invitae put volume heavy and directionally bearish
- 03/06/20
- Largest borrow rate increases among liquid names
- 05/06/20
- Livongo Health call volume above normal and directionally bullish
- 04/02/20
- EXACT Sciences call volume above normal and directionally bullish
- 02/11/20
- EXACT Sciences options imply 10.9% move in share price post-earnings
- 01/24/20
- EXACT Sciences call volume above normal and directionally bullish
- 01/08/20
- EXACT Sciences call volume above normal and directionally bullish
- 06/01/20
- Largest borrow rate increases among liquid names
- 05/19/20
- Largest borrow rate increases among liquid names
- 04/24/20
- BioTelemetry options imply 13.0% move in share price post-earnings
|
| Over a month ago |
|
Conference/Events
|
Virtual Meeting to be… Virtual Meeting to be held on May 26 hosted by Oppenheimer. ShowHide Related Items >><< - 04/27/20
- Amedisys to acquire AseraCare Hospice for $235M in cash
- 04/17/20
- Amedisys receives cash payment of $96M in CARES Act assitance
- 02/18/20
- Fly Intel: After Hours Movers
- 02/18/20
- Amedisys reports Q4 adj. EPS 94c, consensus 93c
- 05/21/20 SunTrust
- SunTrust raises price targets across select Healthcare Services names
- 05/11/20 Raymond James
- Amedisys price target lowered to $210 from $225 at Raymond James
- 05/07/20 Benchmark
- Amedisys downgraded to Hold on limited near-term visibility at Benchmark
- 05/07/20 Benchmark
- Amedisys downgraded to Hold from Buy at Benchmark
- 05/06/20
- Amedisys reports Q1 EPS $1.05, consensus 97c
- 02/18/20
- Amedisys sees FY20 adj. EPS $4.90-$5.13, consensus $4.91
|
|
Conference/Events
|
Virtual Meeting to be… Virtual Meeting to be held on May 26 hosted by Oppenheimer. ShowHide Related Items >><< - $192.10 /
+2.345 (+1.24%) - 04/27/20
- Amedisys to acquire AseraCare Hospice for $235M in cash
- 04/17/20
- Amedisys receives cash payment of $96M in CARES Act assitance
- 02/18/20
- Fly Intel: After Hours Movers
- 02/18/20
- Amedisys reports Q4 adj. EPS 94c, consensus 93c
- $192.10 /
+2.345 (+1.24%) - 05/21/20 SunTrust
- SunTrust raises price targets across select Healthcare Services names
- 05/11/20 Raymond James
- Amedisys price target lowered to $210 from $225 at Raymond James
- 05/07/20 Benchmark
- Amedisys downgraded to Hold on limited near-term visibility at Benchmark
- 05/07/20 Benchmark
- Amedisys downgraded to Hold from Buy at Benchmark
- $192.10 /
+2.345 (+1.24%) - 05/06/20
- Amedisys reports Q1 EPS $1.05, consensus 97c
- 02/18/20
- Amedisys sees FY20 adj. EPS $4.90-$5.13, consensus $4.91
|
|
Recommendations
|
SunTrust analyst David… SunTrust analyst David MacDonald raises his price targets across a number of Healthcare Services names, noting that the re-opening and recovery phase of the pandemic should see the health care system return to more "normalized consumption in the second half of this year and in 2021. The industry's core trends remain solid, reimbursement are largely benign, the underlying demand for healthcare is not going away, and liquidity is key, the analyst tells investors in a research note, adding that he favors names with exposure to Managed Care/Home-Based Care. MacDonald raises his price targets on Amedisys (AMED) to $240 from $225, Anthem (ANTM) to $320 from $280, Quest Diagnostic (DGX) to $130 from $110, Humana (HUM) to $440 from $400, LabCorp (LH) to $220 from $200, LHC Group (LHCG) to $200 from $160, The Pennant Group (PNTG) to $28 from $23, and on UnitedHealth (UNH) to $360 from $340. ShowHide Related Items >><< - 05/15/20
- Lone Pine buys Visa, exits Salesforce in Q1
- 05/15/20
- UnitedHealth, Microsoft collaborate to launch ProtectWell app
- 05/06/20
- SmileDirectClub announces partnerships with U.S. insurers
- 04/23/20
- UnitedHealth, Boston Scientific, Medtronic to deploy 3,000 ventilator devices
- 05/18/20
- The Pennant Group acquires Arizona hospice agencies
- 03/02/20
- The Pennant Group acquires Montana hospice agency, terms not disclosed
- 02/27/20
- The Pennant Group, Scripps Health to form home health joint venture
- 01/02/20
- The Pennant Group acquires home health agency in Nevada
- 04/17/20
- LHC Group to replace Cypress Semiconductor in S&P 400 at open on 4/17
- 04/17/20
- Yeti to replace LHC Group in S&P 600 at open on 4/17
- 05/12/20
- LabCorp expands availability of COVID-19 at-home collection test kit
- 05/05/20
- Adaptive, Microsoft enrolling virtual 'ImmuneRACE' COVID-19 study
- 04/27/20
- LabCorp to offer antibody tests nationwide starting today w/ no up-front cost
- 04/22/20
- LabCorp expands COVID-19 antibody tests to hospitals and organizations
- 05/20/20
- Humana, Healthmap Solutions announce collaboration for CKD care coordination
- 05/05/20
- Humana waives out-of-pocket office visit costs for Medicare Advantage members
- 04/30/20
- Humana posts coverage determination for Aimmune's Palforzia
- 05/11/20
- Quest Diagnostics, Ortho Clinical Diagnostics expand COVID-19 antibody testing
- 05/08/20
- Quest Diagnostics, Peach State Health partner for COVID-19 testing in Georgia
- 04/30/20
- Quest Diagnostics, Clinical Genomics expand strategic relationship in CRC
- 04/29/20
- Centene and Quest Diagnostics partner to increase COVID-19 testing access
- 04/29/20
- Anthem reports approximately 42.1M members at March 31
- 04/29/20
- Anthem temporarily suspends share repurchase activity
- 04/08/20
- Healthcare outperforms after Sanders ends bid for Democratic nomination
- 04/01/20
- Anthem to waive cost share for members in COVID-19 treatment
- $189.76 /
-0.255 (-0.13%) - 04/27/20
- Amedisys to acquire AseraCare Hospice for $235M in cash
- 04/17/20
- Amedisys receives cash payment of $96M in CARES Act assitance
- 02/18/20
- Fly Intel: After Hours Movers
- 02/18/20
- Amedisys reports Q4 adj. EPS 94c, consensus 93c
- $189.76 /
-0.255 (-0.13%) - 05/11/20 Raymond James
- Amedisys price target lowered to $210 from $225 at Raymond James
- 05/07/20 Benchmark
- Amedisys downgraded to Hold on limited near-term visibility at Benchmark
- 05/07/20 Benchmark
- Amedisys downgraded to Hold from Buy at Benchmark
- 03/09/20 Benchmark
- Benchmark upgrades Amedisys to Buy on Home Health boost from crowded hospitals
- 04/28/20
- Fly Intel: Top five analyst upgrades
- 04/28/20 Morgan Stanley
- Morgan Stanley upgrades Quest Diagnostics to Overweight on COVID testing boost
- 04/28/20 Morgan Stanley
- Quest Diagnostics upgraded to Overweight from Equal Weight at Morgan Stanley
- 04/27/20
- Fly Intel: Top five analyst upgrades
- 05/04/20 Mizuho
- Humana price target raised to $420 from $405 at Mizuho
- 04/30/20 Credit Suisse
- Humana price target raised to $423 from $400 at Credit Suisse
- 04/30/20 Oppenheimer
- Humana price target raised to $425 from $400 at Oppenheimer
- 04/29/20 Cantor Fitzgerald
- Humana comments on telephonic sales 'positive' for eHealth, says Cantor
- 05/15/20
- Fly Intel: Top five analyst upgrades
- 05/15/20 Mizuho
- LabCorp upgraded to Buy from Neutral at Mizuho
- 05/13/20 JPMorgan
- Adaptive reported 'healthy' Q1 results, says JPMorgan
- 04/30/20 JPMorgan
- LabCorp price target raised to $188 from $149 at JPMorgan
- 12/06/19 SunTrust
- LHC Group price target raised to $160 from $145 at SunTrust
- 11/01/19 William Blair
- Home health 2020 rate final rule positive for providers, says William Blair
- 10/21/19 Stephens
- LHC Group resumed with an Overweight at Stephens
- 09/16/19 Deutsche Bank
- LHC Group initiated with a Buy at Deutsche Bank
- 01/15/20 SunTrust
- The Pennant Group initiated with a Hold at SunTrust
- 01/15/20 SunTrust
- The Pennant Group initiated with a Hold at SunTrust
- 10/31/19 Stifel
- Ensign Group upgraded to Buy from Hold at Stifel
- 10/22/19 RBC Capital
- The Pennant Group initiated with a Sector Perform at RBC Capital
- 04/24/20 Citi
- UnitedHealth price target lowered to $339 from $346 at Citi
- 04/16/20 Raymond James
- UnitedHealth price target lowered to $325 from $340 at Raymond James
- 04/16/20 Credit Suisse
- UnitedHealth price target lowered to $325 from $330 at Credit Suisse
- 04/16/20 Cowen
- UnitedHealth price target lowered to $320 from $340 at Cowen
- 05/12/20 UBS
- Anthem price target raised to $330 from $307 at UBS
- 04/21/20 Cleveland Research
- Anthem 2020 outlook achievable, possibly beatable, says Cleveland Research
- 04/09/20 Jefferies
- Anthem downgraded to Hold on Commercial Risk at Jefferies
- 04/09/20 Jefferies
- Anthem downgraded to Hold from Buy at Jefferies
- 04/15/20
- UnitedHealth backs FY20 adj. EPS view $16.25-$16.55, consensus $16.22
- 04/15/20
- UnitedHealth reports Q1 adj. EPS $3.72, consensus $3.63
- 04/14/20
- Notable companies reporting before tomorrow's open
- 01/15/20
- UnitedHealth sees FY20 revenue around $262B, consensus $242.23B
- 03/04/20
- The Pennant Group sees FY20 EPS 53c-58c, two-estimate consensus 57c
- 03/04/20
- The Pennant Group reports Q4 EPS 16c, two-estimate consensus 16c
- 05/07/20
- LHC Group reports Q1 EPS 75c, consensus 69c
- 02/26/20
- LHC Group sees FY20 EPS $4.60-$4.80, consensus $4.74
- 02/26/20
- LHC Group sees Q1 EPS 70c-80c, consensus 97c
- 02/26/20
- LHC Group reports Q4 adj. EPS $1.15, consensus $1.13
- 04/29/20
- LabCorp withdraws 2020 guidance, temporarily suspends share repurchases
- 04/29/20
- LabCorp withdraws 2020 guidance, temporarily suspends share repurchases
- 04/29/20
- LabCorp reports Q1 adjusted EPS 2.37, consensus $1.95
- 04/29/20
- Humana backs FY20 adjusted EPS view $18.25-$18.75, consensus $18.44
- 04/29/20
- Humana reports Q1 adjusted EPS $5.40, consensus $4.68
- 04/22/20
- Quest Diagnostics reports Q1 adj. EPS 94c, consensus 89c
- 04/21/20
- Notable companies reporting before tomorrow's open
- 01/30/20
- Quest Diagnostics sees FY20 adj. EPS over $6.60, consensus $6.73
- 04/29/20
- Anthem backs FY20 adjusted EPS view greater than $22.30, consensus $22.02
- 04/29/20
- Anthem reports Q1 adjusted EPS $6.48, consensus $6.48
- 04/28/20
- Notable companies reporting before tomorrow's open
- $189.76 /
-0.255 (-0.13%) - 05/06/20
- Amedisys reports Q1 EPS $1.05, consensus 97c
- 02/18/20
- Amedisys sees FY20 adj. EPS $4.90-$5.13, consensus $4.91
- 05/04/20
- UnitedHealth, insurers look to help hospitals, doctors amid pandemic, WSJ says
- 04/27/20
- UnitedHealth in advanced talks to buy AbleTo for roughly $470M, CNBC says
- 01/15/20
- LHC Group named as new short idea by Spruce Point
- 03/29/20
- Cigna, Humana waiving cost-sharing for COVID-19 treatments, Bloomberg says
- 05/04/20
- Supreme Court decision clears way for insurance industry payouts, WSJ reports
- 04/27/20
- Supreme court rules in health insurers' favor in Obamacare fight, Bloomberg says
- 04/18/20
- Health insurers could come under political pressure again, Barron's says
- 03/07/20
- J&J, Amgen among healthy dividend stocks as COVID-19 fears grow, Barron's says
- 04/15/20
- Fly Intel: Pre-market Movers
- 03/25/20
- Fly Intel: Wall Street's top stories for Wednesday
- 04/29/20
- Fly Intel: Pre-market Movers
- 04/28/20
- Analyst says buy Quest Diagnostics amid direct-to-consumer COVID-19 test launch
- 04/27/20
- Fly Intel: After-Hours Movers
- 04/21/20
- Fly Intel: Wall Street's top stories for Tuesday
- 03/10/20
- Fly Intel: Wall Street's top stories at midday
- 04/28/20
- Fly Intel: Pre-market Movers
- 04/22/20
- Fly Intel: Pre-market Movers
- 03/14/20
- Week in Review: How Trump's policies moved stocks
- 03/04/20
- Fly Intel: Wall Street's top stories for Wednesday
- 03/04/20
- Fly Intel: Wall Street's top stories at midday
- 03/04/20
- UnitedHealth, Centene jump after Biden's Super Tuesday comeback
- 04/15/20
- Early notable gainers among liquid option names on April 15th
- 04/15/20
- Unusually active option classes on open April 15th
- 03/06/20
- UnitedHealth put volume heavy and directionally bearish
- 04/27/20
- Early notable gainers among liquid option names on April 27th
- 03/25/20
- Early notable gainers among liquid option names on March 25th
- 02/12/20
- Humana call volume above normal and directionally bullish
- 02/05/20
- Early notable gainers among liquid option names on February 5th
- 05/20/20
- Early notable gainers among liquid option names on May 20th
- 05/05/20
- Anthem call buyer realizes 19% same-day gains
- 03/06/20
- Anthem put volume heavy and directionally bearish
- 03/04/20
- Early notable gainers among liquid option names on March 4th
- 02/04/20
- Anthem put buyer realizes 4% same-day gains
|
|
Conference/Events
|
Global Healthcare Virtual… Global Healthcare Virtual Conference will be held on May 18-20. ShowHide Related Items >><< - 05/18/20
- Physicians Realty to replace West Pharmaceutical in S&P 400 at open on 5/22
- 05/18/20
- West Pharmaceutical to replace Helmerich & Payne in S&P 500 at open on 5/22
- 12/13/19
- West Pharmaceutical announces 848K share repurchase authorization
- 03/18/20
- Viking Therapeutics announces $50M stock repurchase program
- 11/21/19
- Data on Viking Therapeutics' VK2809 study in NASH posted to ClinicalTrials.gov
- 04/27/20
- Universal Health suspends stock repurchase program, payment of dividend
- 03/29/20
- Fly Intel: Top five weekend stock stories
- 03/17/20
- VP Pence says he and President Trump to meet today on hospital supply chains
- 03/13/20
- Trump says asking all hospitals to engage emergency response measures
- $346.33 /
-6.665 (-1.89%) - 04/29/20
- Teleflex awarded Central Venous Access, Arterial Access agreements with Premier
- 02/20/20
- Teleflex acquires IWG High Performance Conductors
- 02/14/20
- Teleflex announces worldwide recall of Comfort Flo humidification system
- 01/22/20
- Teleflex receives FDA clearance for Wattson temporary pacing guidewire
- 05/08/20
- RedHill Biopharma gets FDA OK for COVID-19 clinical study with opaganib
- 05/05/20
- RedHill Biopharma announces publication of results of Phase 3 study of Talicia
- 04/28/20
- RedHill announces preferred brand position on NetResults National Formulary
- 04/27/20
- RedHill Biopharma: Six COVID-19 patients treated with opaganib show improvement
- 05/14/20
- Nevro announces CE mark approval for the Senza Omnia SCS system
- 05/05/20
- Nevro withdraws previously announced FY20 guidance
- 04/09/20
- Nevro says court upholds patent claims validity in Boston Scientific case
- 02/28/20
- Nevro files patent infringement lawsuit against Nalu Medical in the U.S.
- 05/15/20
- Lone Pine buys Visa, exits Salesforce in Q1
- 05/05/20
- Humana waives out-of-pocket office visit costs for Medicare Advantage members
- 04/30/20
- Humana posts coverage determination for Aimmune's Palforzia
- 04/02/20
- Humana announces health care provider initiative amid COVID-19 pandemic
- 05/01/20
- Hill-Rom announces initiatives in response to COVID-19 pandemic
- 03/24/20
- Hill-Rom announces growth in demand of several critical products
- 03/09/20
- Hill Rom Holdings trading resumes
- 03/09/20
- Hill Rom Holdings trading halted, volatility trading pause
- 03/25/20
- Establishment Labs receives issuance for patent covering implant surface tech
- 03/24/20
- Establishment Labs Holdings Inc trading resumes
- 03/24/20
- Establishment Labs Holdings Inc trading halted, volatility trading pause
- 03/18/20
- Establishment Labs Holdings Inc trading halted, volatility trading pause
- 05/07/20
- Codexis withdraws FY20 financial guidance
- 05/05/20
- Codexis names Stefan Lutz SVP, research, Karl Schoene SVP, development
- 03/23/20
- Codexis signs strategic collaboration, license agreement with Takeda
- 01/10/20
- Codexis, Nestle Health Science sign development agreement for CDX-7108
APLT Applied Therapeutics - 04/21/20
- Applied Therapeutics announces data from Phase 2 ACTION-Galactosemia trial
- 04/02/20
- Applied Therapeutics announces IND, investigator-initiated studies of AT-001
- 03/16/20
- Applied Therapeutics Inc trading halted, volatility trading pause
- 03/13/20
- Applied Therapeutics expects topline data from ARISE-HF trial in 2021
- 02/06/20
- AngioDynamics appoints Stephen Trowbridge as CFO
- 01/16/20
- AngioDynamics launches PATHFINDER I pilot study
- 01/07/20
- Fly Intel: Pre-market Movers
- 01/07/20
- AngioDynamics up 3.4% after reporting Q2 results, reaffirming FY20 guidance
- 04/27/20
- Amedisys to acquire AseraCare Hospice for $235M in cash
- 04/17/20
- Amedisys receives cash payment of $96M in CARES Act assitance
- 02/18/20
- Fly Intel: After Hours Movers
- 02/18/20
- Amedisys reports Q4 adj. EPS 94c, consensus 93c
- 05/05/20
- AdaptHealth sees FY20 revenue $790M-$808M, consensus $791.17M
- 04/14/20
- AdaptHealth appoints Andy Palan as Chief Technology Officer
- 03/17/20
- AdaptHealth Corporation (Class A Stock) trading resumes
- 03/17/20
- AdaptHealth Corporation (Class A Stock) trading halted, volatility trading pause
- 02/27/20 Roth Capital
- RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
- 07/12/19 WBB Securities
- RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
- 04/08/20
- Fly Intel: Top five analyst downgrades
- 04/08/20 KeyBanc
- AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc
- 04/07/20 KeyBanc
- AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc
- 12/30/19 Stifel
- Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel
- 03/10/20 Benchmark
- Codexis initiated with a Buy at Benchmark
- 02/28/20 Deutsche Bank
- AdaptHealth price target raised to $19 from $12 at Deutsche Bank
- 01/31/20
- Fly Intel: Top five analyst initiations
- 01/30/20 Stifel
- AdaptHealth initiated with a Buy at Stifel
- 01/07/20 Jefferies
- Jefferies starts AdaptHealth at Buy with $15 price target
APLT Applied Therapeutics - 04/22/20
- Fly Intel: Top five analyst initiations
- 04/22/20 Goldman Sachs
- Applied Therapeutics initiated with a Buy at Goldman Sachs
- 02/27/20 Barclays
- Applied Therapeutics initiated with an Overweight at Barclays
- 02/27/20 Barclays
- Applied Therapeutics initiated with an Overweight at Barclays
- $346.33 /
-6.665 (-1.89%) - 05/01/20 Piper Sandler
- Teleflex price target lowered to $375 from $425 at Piper Sandler
- 04/03/20 Raymond James
- Teleflex price target lowered to $360 from $450 at Raymond James
- 02/20/20 Piper Sandler
- Teleflex price target raised to $425 from $400 at Piper Sandler
- 12/12/19 Wells Fargo
- SeaSpine, Glaukos double-downgraded to Underweight at Wells Fargo
- 04/29/20 Deutsche Bank
- Universal Health price target lowered to $135 from $165 at Deutsche Bank
- 04/28/20 Citi
- Universal Health price target lowered to $128 from $157 at Citi
- 03/26/20 JPMorgan
- Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
- 03/23/20 BofA
- Universal Health downgraded to Neutral on Vegas recession risk at BofA
- 03/17/20 Barclays
- Hill-Rom upgraded to Overweight from Equal Weight at Barclays
- 12/17/19 Morgan Stanley
- Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley
- 12/17/19 Morgan Stanley
- Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley
- 06/27/19 Raymond James
- Hill-Rom's DoD contract win a 'nice development,' says Raymond James
- 05/06/20 Citi
- Nevro price target raised to $137 from $130 at Citi
- 04/02/20 SunTrust
- Nevro price target lowered to $120 from $146 at SunTrust
- 04/02/20 Wells Fargo
- Nevro price target lowered to $126 from $158 at Wells Fargo
- 03/04/20 Citi
- Nevro initiated with a Buy at Citi
- 05/11/20 Raymond James
- Amedisys price target lowered to $210 from $225 at Raymond James
- 05/07/20 Benchmark
- Amedisys downgraded to Hold on limited near-term visibility at Benchmark
- 05/07/20 Benchmark
- Amedisys downgraded to Hold from Buy at Benchmark
- 03/09/20 Benchmark
- Benchmark upgrades Amedisys to Buy on Home Health boost from crowded hospitals
- 05/14/20
- Fly Intel: Top five analyst initiations
- 05/14/20 Goldman Sachs
- Establishment Labs initiated with a Neutral at Goldman Sachs
- 01/03/20 BTIG
- Zimmer Biomet, Staar Surgical, ViewRay among top 2020 picks at BTIG
- 07/24/19 Wells Fargo
- Allergan recall to benefit Establishment and Sientra, says Wells Fargo
- 05/04/20 Mizuho
- Humana price target raised to $420 from $405 at Mizuho
- 04/30/20 Credit Suisse
- Humana price target raised to $423 from $400 at Credit Suisse
- 04/30/20 Oppenheimer
- Humana price target raised to $425 from $400 at Oppenheimer
- 04/29/20 Cantor Fitzgerald
- Humana comments on telephonic sales 'positive' for eHealth, says Cantor
- 05/05/20 Chardan
- Viking Therapeutics initiated with a Buy at Chardan
- 05/04/20 B. Riley FBR
- Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
- 05/01/20 BTIG
- Viking Therapeutics initiated with a Buy at BTIG
- 02/27/20 H.C. Wainwright
- Viking Therapeutics price target lowered to $18 from $31 at H.C. Wainwright
- 04/24/20 BofA
- West Pharmaceutical upgraded to Neutral from Underperform at BofA
- 04/24/20 BofA
- West Pharmaceutical upgraded to Neutral from Underperform at BofA
- 12/12/19
- Fly Intel: Top five analyst downgrades
- 12/12/19 BofA
- West Pharmaceutical downgraded to Underperform from Neutral at BofA/Merrill
- 04/23/20
- West Pharmaceutical raises FY20 adj. EPS view to $3.52-$3.62 from $3.45-$3.55
- 04/23/20
- West Pharmaceutical reports Q1 adj. EPS $1.01, consensus 82c
- 02/13/20
- West Pharmaceutical sees FY20 EPS $3.45-$3.55, consensus $3.46
- 02/13/20
- West Pharmaceutical reports Q4 adj. EPS 82c, consensus 72c
- 04/30/20
- Viking Therapeutics reports Q1 EPS (13c), consensus (12c)
- 02/26/20
- Viking Therapeutics reports Q4 EPS (10c), consensus (13c)
- 04/27/20
- Universal Health withdraws FY20 guidance
- 04/27/20
- Universal Health reports Q1 adjusted EPS $1.73, consensus $2.55
- 04/27/20
- Notable companies reporting after market close
- 02/26/20
- Universal Health sees FY20 adjusted EPS $10.30-$11.00, consensus $10.75
- $346.33 /
-6.665 (-1.89%) - 04/30/20
- Teleflex withdraws 2020 guidance
- 04/30/20
- Teleflex reports Q1 adjusted EPS $2.72, consensus $2.35
- 02/20/20
- Teleflex sees FY20 adjusted EPS $12.50-$12.70, consensus $12.68
- 02/20/20
- Teleflex reports Q4 adjusted EPS $3.28, consensus $3.22
- 03/04/20
- RedHill Biopharma reports FY19 EPS (14c), consensus ($1.07)
- 05/05/20
- Nevro reports Q1 EPS (78c), consensus (97c)
- 04/01/20
- Nevro sees Q1 revenue $86.4M-$86.9M, consensus $96.96M
- 04/01/20
- Nevro withdraws FY20 guidance issued on February 25
- 02/25/20
- Nevro sees FY20 revenue $435M-$440M, consensus $437.06M
- 04/29/20
- Humana backs FY20 adjusted EPS view $18.25-$18.75, consensus $18.44
- 04/29/20
- Humana reports Q1 adjusted EPS $5.40, consensus $4.68
- 04/28/20
- Notable companies reporting before tomorrow's open
- 05/01/20
- Hill-Rom reports Q2 adj. EPS $1.28, consensus $1.15
- 02/26/20
- Hill-Rom raises quarterly dividend to 22c per share from 21c per share
- 01/24/20
- Hill-Rom raises FY20 EPS view to $5.50-$5.56 from $5.46-$5.56, consensus $5.52
- 01/24/20
- Hill-Rom sees Q2 adj. EPS $1.14-$1.16, consensus $1.24
- 05/07/20
- Establishment Labs reports Q1 EPS (79c), consensus (31c)
- 03/16/20
- Establishment Labs sees Q1 revenue $23M-$25M, consensus $25.1M
- 03/16/20
- Establishment Labs not providing FY20 guidance amid COVID-19 pandemic
- 03/16/20
- Establishment Labs reports FY19 EPS ($1.86), consensus ($2.18)
- 05/07/20
- Codexis reports Q1 adjusted EPS (9c), consensus (14c)
- 02/27/20
- Codexis reports Q4 EPS 2c, consensus 0c
APLT Applied Therapeutics - 05/11/20
- Applied Therapeutics reports Q1 EPS (59c), consensus (82c)
- 03/13/20
- Applied Therapeutics reports FY19 EPS ($3.55), consensus ($3.00)
- 04/07/20
- AngioDynamics withdraws FY20 guidance due to COVID-19
- 04/07/20
- AngioDynamics reports Q3 adj. EPS 1c, consensus (3c)
- 01/07/20
- AngioDynamics backs FY20 adj. EPS view of 10c-15c, consensus 13c
- 01/07/20
- AngioDynamics reports Q2 adj. EPS 6c, consensus 2c
- 05/06/20
- Amedisys reports Q1 EPS $1.05, consensus 97c
- 02/18/20
- Amedisys sees FY20 adj. EPS $4.90-$5.13, consensus $4.91
- 05/05/20
- AdaptHealth reports Q1 EPS 0c, consensus 12c
- 02/25/20
- AdaptHealth raises FY20 revenue view to $765M-$782M, consensus $770.94M
- 02/25/20
- AdaptHealth reports Q4 EPS (10c), consensus 6c
- 05/03/20
- U.S. hospitals promise new safety measures to ease patient fears, Reuters says
- 04/17/20
- New stimulus deal could have $75B for hospitals, Politco says
- 03/29/20
- Trump accuses hospitals of hoarding ventilators, Reuters reports
- 03/18/20
- U.S COVID-19 plan lays out possible '18-month 'pandemic,' NY Times says
- 05/04/20
- Supreme Court decision clears way for insurance industry payouts, WSJ reports
- 04/27/20
- Supreme court rules in health insurers' favor in Obamacare fight, Bloomberg says
- 04/18/20
- Health insurers could come under political pressure again, Barron's says
- 03/29/20
- Cigna, Humana waiving cost-sharing for COVID-19 treatments, Bloomberg says
- 05/06/20
- Novo Nordisk slips as analysts discuss NASH data, read-through to peers
- 04/27/20
- Fly Intel: After-Hours Movers
- 03/14/20
- Week in Review: How Trump's policies moved stocks
- 12/21/19
- Week in Review: How Trump's policies moved stocks
- 04/01/20
- Fly Intel: After-Hours Movers
- 01/27/20
- Fly Intel: Wall Street's top stories for Monday
- 04/29/20
- Fly Intel: Pre-market Movers
- 03/10/20
- Fly Intel: Wall Street's top stories at midday
- 03/04/20
- Fly Intel: Wall Street's top stories for Wednesday
APLT Applied Therapeutics - 01/08/20
- Fly Intel: Wall Street's top stories for Wednesday
- 01/08/20
- Fly Intel: Wall Street's top stories at midday
- 04/07/20
- Fly Intel: Pre-market Movers
- 11/26/19
- Viking Therapeutics put volume heavy and directionally bearish
- 03/25/20
- Early notable gainers among liquid option names on March 25th
- 03/04/20
- Early notable gainers among liquid option names on March 4th
- 02/12/20
- Humana call volume above normal and directionally bullish
- 02/05/20
- Early notable gainers among liquid option names on February 5th
|
|
Conference/Events
|
Global Healthcare Virtual… Global Healthcare Virtual Conference will be held on May 18-20. ShowHide Related Items >><< - 05/18/20
- Physicians Realty to replace West Pharmaceutical in S&P 400 at open on 5/22
- 05/18/20
- West Pharmaceutical to replace Helmerich & Payne in S&P 500 at open on 5/22
- 12/13/19
- West Pharmaceutical announces 848K share repurchase authorization
- 03/18/20
- Viking Therapeutics announces $50M stock repurchase program
- 11/21/19
- Data on Viking Therapeutics' VK2809 study in NASH posted to ClinicalTrials.gov
- 11/19/19
- Fly Intel: Pre-market Movers
- 11/19/19
- Viking Therapeutics begins Phase 2b clinical trial of VK2809
- 04/27/20
- Universal Health suspends stock repurchase program, payment of dividend
- 03/29/20
- Fly Intel: Top five weekend stock stories
- 03/17/20
- VP Pence says he and President Trump to meet today on hospital supply chains
- 03/13/20
- Trump says asking all hospitals to engage emergency response measures
- $353.00 /
+18.395 (+5.50%) - 04/29/20
- Teleflex awarded Central Venous Access, Arterial Access agreements with Premier
- 02/20/20
- Teleflex acquires IWG High Performance Conductors
- 02/14/20
- Teleflex announces worldwide recall of Comfort Flo humidification system
- 01/22/20
- Teleflex receives FDA clearance for Wattson temporary pacing guidewire
- 05/08/20
- RedHill Biopharma gets FDA OK for COVID-19 clinical study with opaganib
- 05/05/20
- RedHill Biopharma announces publication of results of Phase 3 study of Talicia
- 04/28/20
- RedHill announces preferred brand position on NetResults National Formulary
- 04/27/20
- RedHill Biopharma: Six COVID-19 patients treated with opaganib show improvement
- 05/14/20
- Nevro announces CE mark approval for the Senza Omnia SCS system
- 05/05/20
- Nevro withdraws previously announced FY20 guidance
- 04/09/20
- Nevro says court upholds patent claims validity in Boston Scientific case
- 02/28/20
- Nevro files patent infringement lawsuit against Nalu Medical in the U.S.
- 05/15/20
- Lone Pine buys Visa, exits Salesforce in Q1
- 05/05/20
- Humana waives out-of-pocket office visit costs for Medicare Advantage members
- 04/30/20
- Humana posts coverage determination for Aimmune's Palforzia
- 04/02/20
- Humana announces health care provider initiative amid COVID-19 pandemic
- 05/01/20
- Hill-Rom announces initiatives in response to COVID-19 pandemic
- 03/24/20
- Hill-Rom announces growth in demand of several critical products
- 03/09/20
- Hill Rom Holdings trading resumes
- 03/09/20
- Hill Rom Holdings trading halted, volatility trading pause
- 03/25/20
- Establishment Labs receives issuance for patent covering implant surface tech
- 03/24/20
- Establishment Labs Holdings Inc trading resumes
- 03/24/20
- Establishment Labs Holdings Inc trading halted, volatility trading pause
- 03/18/20
- Establishment Labs Holdings Inc trading halted, volatility trading pause
- 05/07/20
- Codexis withdraws FY20 financial guidance
- 05/05/20
- Codexis names Stefan Lutz SVP, research, Karl Schoene SVP, development
- 03/23/20
- Codexis signs strategic collaboration, license agreement with Takeda
- 01/10/20
- Codexis, Nestle Health Science sign development agreement for CDX-7108
APLT Applied Therapeutics - 04/21/20
- Applied Therapeutics announces data from Phase 2 ACTION-Galactosemia trial
- 04/02/20
- Applied Therapeutics announces IND, investigator-initiated studies of AT-001
- 03/16/20
- Applied Therapeutics Inc trading halted, volatility trading pause
- 03/13/20
- Applied Therapeutics expects topline data from ARISE-HF trial in 2021
- 02/06/20
- AngioDynamics appoints Stephen Trowbridge as CFO
- 01/16/20
- AngioDynamics launches PATHFINDER I pilot study
- 01/07/20
- Fly Intel: Pre-market Movers
- 01/07/20
- AngioDynamics up 3.4% after reporting Q2 results, reaffirming FY20 guidance
- 04/27/20
- Amedisys to acquire AseraCare Hospice for $235M in cash
- 04/17/20
- Amedisys receives cash payment of $96M in CARES Act assitance
- 02/18/20
- Fly Intel: After Hours Movers
- 02/18/20
- Amedisys reports Q4 adj. EPS 94c, consensus 93c
- 05/05/20
- AdaptHealth sees FY20 revenue $790M-$808M, consensus $791.17M
- 04/14/20
- AdaptHealth appoints Andy Palan as Chief Technology Officer
- 03/17/20
- AdaptHealth Corporation (Class A Stock) trading resumes
- 03/17/20
- AdaptHealth Corporation (Class A Stock) trading halted, volatility trading pause
- 02/27/20 Roth Capital
- RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
- 07/12/19 WBB Securities
- RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
- 04/08/20
- Fly Intel: Top five analyst downgrades
- 04/08/20 KeyBanc
- AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc
- 04/07/20 KeyBanc
- AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc
- 12/30/19 Stifel
- Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel
- 03/10/20 Benchmark
- Codexis initiated with a Buy at Benchmark
- 02/28/20 Deutsche Bank
- AdaptHealth price target raised to $19 from $12 at Deutsche Bank
- 01/31/20
- Fly Intel: Top five analyst initiations
- 01/30/20 Stifel
- AdaptHealth initiated with a Buy at Stifel
- 01/07/20 Jefferies
- Jefferies starts AdaptHealth at Buy with $15 price target
APLT Applied Therapeutics - 04/22/20
- Fly Intel: Top five analyst initiations
- 04/22/20 Goldman Sachs
- Applied Therapeutics initiated with a Buy at Goldman Sachs
- 02/27/20 Barclays
- Applied Therapeutics initiated with an Overweight at Barclays
- 02/27/20 Barclays
- Applied Therapeutics initiated with an Overweight at Barclays
- $353.00 /
+18.395 (+5.50%) - 05/01/20 Piper Sandler
- Teleflex price target lowered to $375 from $425 at Piper Sandler
- 04/03/20 Raymond James
- Teleflex price target lowered to $360 from $450 at Raymond James
- 02/20/20 Piper Sandler
- Teleflex price target raised to $425 from $400 at Piper Sandler
- 12/12/19 Wells Fargo
- SeaSpine, Glaukos double-downgraded to Underweight at Wells Fargo
- 04/29/20 Deutsche Bank
- Universal Health price target lowered to $135 from $165 at Deutsche Bank
- 04/28/20 Citi
- Universal Health price target lowered to $128 from $157 at Citi
- 03/26/20 JPMorgan
- Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
- 03/23/20 BofA
- Universal Health downgraded to Neutral on Vegas recession risk at BofA
- 03/17/20 Barclays
- Hill-Rom upgraded to Overweight from Equal Weight at Barclays
- 12/17/19 Morgan Stanley
- Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley
- 12/17/19 Morgan Stanley
- Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley
- 06/27/19 Raymond James
- Hill-Rom's DoD contract win a 'nice development,' says Raymond James
- 05/06/20 Citi
- Nevro price target raised to $137 from $130 at Citi
- 04/02/20 SunTrust
- Nevro price target lowered to $120 from $146 at SunTrust
- 04/02/20 Wells Fargo
- Nevro price target lowered to $126 from $158 at Wells Fargo
- 03/04/20 Citi
- Nevro initiated with a Buy at Citi
- 05/11/20 Raymond James
- Amedisys price target lowered to $210 from $225 at Raymond James
- 05/07/20 Benchmark
- Amedisys downgraded to Hold on limited near-term visibility at Benchmark
- 05/07/20 Benchmark
- Amedisys downgraded to Hold from Buy at Benchmark
- 03/09/20 Benchmark
- Benchmark upgrades Amedisys to Buy on Home Health boost from crowded hospitals
- 05/14/20
- Fly Intel: Top five analyst initiations
- 05/14/20 Goldman Sachs
- Establishment Labs initiated with a Neutral at Goldman Sachs
- 01/03/20 BTIG
- Zimmer Biomet, Staar Surgical, ViewRay among top 2020 picks at BTIG
- 07/24/19 Wells Fargo
- Allergan recall to benefit Establishment and Sientra, says Wells Fargo
- 05/04/20 Mizuho
- Humana price target raised to $420 from $405 at Mizuho
- 04/30/20 Credit Suisse
- Humana price target raised to $423 from $400 at Credit Suisse
- 04/30/20 Oppenheimer
- Humana price target raised to $425 from $400 at Oppenheimer
- 04/29/20 Cantor Fitzgerald
- Humana comments on telephonic sales 'positive' for eHealth, says Cantor
- 05/05/20 Chardan
- Viking Therapeutics initiated with a Buy at Chardan
- 05/04/20 B. Riley FBR
- Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
- 05/01/20 BTIG
- Viking Therapeutics initiated with a Buy at BTIG
- 02/27/20 H.C. Wainwright
- Viking Therapeutics price target lowered to $18 from $31 at H.C. Wainwright
- 04/24/20 BofA
- West Pharmaceutical upgraded to Neutral from Underperform at BofA
- 04/24/20 BofA
- West Pharmaceutical upgraded to Neutral from Underperform at BofA
- 12/12/19
- Fly Intel: Top five analyst downgrades
- 12/12/19 BofA
- West Pharmaceutical downgraded to Underperform from Neutral at BofA/Merrill
- 04/23/20
- West Pharmaceutical raises FY20 adj. EPS view to $3.52-$3.62 from $3.45-$3.55
- 04/23/20
- West Pharmaceutical reports Q1 adj. EPS $1.01, consensus 82c
- 02/13/20
- West Pharmaceutical sees FY20 EPS $3.45-$3.55, consensus $3.46
- 02/13/20
- West Pharmaceutical reports Q4 adj. EPS 82c, consensus 72c
- 04/30/20
- Viking Therapeutics reports Q1 EPS (13c), consensus (12c)
- 02/26/20
- Viking Therapeutics reports Q4 EPS (10c), consensus (13c)
- 04/27/20
- Universal Health withdraws FY20 guidance
- 04/27/20
- Universal Health reports Q1 adjusted EPS $1.73, consensus $2.55
- 04/27/20
- Notable companies reporting after market close
- 02/26/20
- Universal Health sees FY20 adjusted EPS $10.30-$11.00, consensus $10.75
- $353.00 /
+18.395 (+5.50%) - 04/30/20
- Teleflex withdraws 2020 guidance
- 04/30/20
- Teleflex reports Q1 adjusted EPS $2.72, consensus $2.35
- 02/20/20
- Teleflex sees FY20 adjusted EPS $12.50-$12.70, consensus $12.68
- 02/20/20
- Teleflex reports Q4 adjusted EPS $3.28, consensus $3.22
- 03/04/20
- RedHill Biopharma reports FY19 EPS (14c), consensus ($1.07)
- 11/19/19
- RedHill Biopharma reports Q3 EPS (3c), consensus (38c)
- 05/05/20
- Nevro reports Q1 EPS (78c), consensus (97c)
- 04/01/20
- Nevro sees Q1 revenue $86.4M-$86.9M, consensus $96.96M
- 04/01/20
- Nevro withdraws FY20 guidance issued on February 25
- 02/25/20
- Nevro sees FY20 revenue $435M-$440M, consensus $437.06M
- 04/29/20
- Humana backs FY20 adjusted EPS view $18.25-$18.75, consensus $18.44
- 04/29/20
- Humana reports Q1 adjusted EPS $5.40, consensus $4.68
- 04/28/20
- Notable companies reporting before tomorrow's open
- 05/01/20
- Hill-Rom reports Q2 adj. EPS $1.28, consensus $1.15
- 02/26/20
- Hill-Rom raises quarterly dividend to 22c per share from 21c per share
- 01/24/20
- Hill-Rom raises FY20 EPS view to $5.50-$5.56 from $5.46-$5.56, consensus $5.52
- 01/24/20
- Hill-Rom sees Q2 adj. EPS $1.14-$1.16, consensus $1.24
- 05/07/20
- Establishment Labs reports Q1 EPS (79c), consensus (31c)
- 03/16/20
- Establishment Labs sees Q1 revenue $23M-$25M, consensus $25.1M
- 03/16/20
- Establishment Labs not providing FY20 guidance amid COVID-19 pandemic
- 03/16/20
- Establishment Labs reports FY19 EPS ($1.86), consensus ($2.18)
- 05/07/20
- Codexis reports Q1 adjusted EPS (9c), consensus (14c)
- 02/27/20
- Codexis reports Q4 EPS 2c, consensus 0c
APLT Applied Therapeutics - 05/11/20
- Applied Therapeutics reports Q1 EPS (59c), consensus (82c)
- 03/13/20
- Applied Therapeutics reports FY19 EPS ($3.55), consensus ($3.00)
- 04/07/20
- AngioDynamics withdraws FY20 guidance due to COVID-19
- 04/07/20
- AngioDynamics reports Q3 adj. EPS 1c, consensus (3c)
- 01/07/20
- AngioDynamics backs FY20 adj. EPS view of 10c-15c, consensus 13c
- 01/07/20
- AngioDynamics reports Q2 adj. EPS 6c, consensus 2c
- 05/06/20
- Amedisys reports Q1 EPS $1.05, consensus 97c
- 02/18/20
- Amedisys sees FY20 adj. EPS $4.90-$5.13, consensus $4.91
- 05/05/20
- AdaptHealth reports Q1 EPS 0c, consensus 12c
- 02/25/20
- AdaptHealth raises FY20 revenue view to $765M-$782M, consensus $770.94M
- 02/25/20
- AdaptHealth reports Q4 EPS (10c), consensus 6c
- 05/03/20
- U.S. hospitals promise new safety measures to ease patient fears, Reuters says
- 04/17/20
- New stimulus deal could have $75B for hospitals, Politco says
- 03/29/20
- Trump accuses hospitals of hoarding ventilators, Reuters reports
- 03/18/20
- U.S COVID-19 plan lays out possible '18-month 'pandemic,' NY Times says
- 05/04/20
- Supreme Court decision clears way for insurance industry payouts, WSJ reports
- 04/27/20
- Supreme court rules in health insurers' favor in Obamacare fight, Bloomberg says
- 04/18/20
- Health insurers could come under political pressure again, Barron's says
- 03/29/20
- Cigna, Humana waiving cost-sharing for COVID-19 treatments, Bloomberg says
- 05/06/20
- Novo Nordisk slips as analysts discuss NASH data, read-through to peers
- 04/27/20
- Fly Intel: After-Hours Movers
- 03/14/20
- Week in Review: How Trump's policies moved stocks
- 12/21/19
- Week in Review: How Trump's policies moved stocks
- 04/01/20
- Fly Intel: After-Hours Movers
- 01/27/20
- Fly Intel: Wall Street's top stories for Monday
- 04/29/20
- Fly Intel: Pre-market Movers
- 03/10/20
- Fly Intel: Wall Street's top stories at midday
- 03/04/20
- Fly Intel: Wall Street's top stories for Wednesday
APLT Applied Therapeutics - 01/08/20
- Fly Intel: Wall Street's top stories for Wednesday
- 01/08/20
- Fly Intel: Wall Street's top stories at midday
- 04/07/20
- Fly Intel: Pre-market Movers
- 11/26/19
- Viking Therapeutics put volume heavy and directionally bearish
- 03/25/20
- Early notable gainers among liquid option names on March 25th
- 03/04/20
- Early notable gainers among liquid option names on March 4th
- 02/12/20
- Humana call volume above normal and directionally bullish
- 02/05/20
- Early notable gainers among liquid option names on February 5th
|